CD73 (Immuno-Oncology Target)(NT5E/2646) , Biotin conjugate , 0.1mg / mL

CD73 is a membrane-bound extracellular enzyme overexpressed in several cancer types. Its expression has been linked to poor prognosis in melanoma , colorectal , gastric , triple negative breast cancer , and to a pro-metastatic phenotype in prostate cancer. Together with CD39 , it plays a major role in promoting immunosuppression through the pathway degrading adenosine triphosphate (ATP) into adenosine. Within the tumor microenvironment , ATP promotes immune cell-mediated killing of cancer cells. In contrast , adenosine accumulation causes immune suppression , dysregulation of immune cell infiltrates and stimulates angiogenesis resulting in tumor spreading. CD73 is active on the last step of the degradation pathway , where it is the enzyme that actually degrades AMP into adenosine. CD73-blockade promotes anti-tumor immunity by reducing adenosine accumulation. Accordingly , anti-CD73 mAbs stimulate anti-tumor immunity and reduce tumor metastasis in Mouse tumor models , and could enhance the efficacy of treatment with anti-PD1 or anti-CTLA4 antibodies. Primary antibodies are available purified , or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets , because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.